Trials / Completed
CompletedNCT01660620
Topical Betaxolol for the Prevention of Retinopathy of Prematurity
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Smith-Kettlewell Eye Research Institute · Academic / Other
- Sex
- All
- Age
- 32 Weeks – 32 Weeks
- Healthy volunteers
- Not accepted
Summary
We hypothesize that topical betaxolol will reduce the development of severe retinopathy of prematurity.
Detailed description
The drug is administered twice a day between 32 and 35 weeks gestational age, at a t ime when ROP is most likely to arise.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Betaxolol | |
| DRUG | topical betaxolol | given topically |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2011-11-01
- Completion
- 2011-11-01
- First posted
- 2012-08-08
- Last updated
- 2013-01-03
Source: ClinicalTrials.gov record NCT01660620. Inclusion in this directory is not an endorsement.